The renin-angiotensin system modulates inflammatory processes in atherosclerosis: Evidence from basic research and clinical studies

Mediators of Inflammation

Volumn 2009, Issue , 2009, Pages

  Montecucco, Fabrizio ^a   Pende, Aldo ^b   MacH, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; OMAPATRILAT; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; RENIN;

ACUTE HEART INFARCTION; ALBUMINURIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDITIS; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COUGHING; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; EVIDENCE BASED PRACTICE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; INHIBITION KINETICS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATOID ARTHRITIS; SODIUM RETENTION; STROKE; VASCULAR DISEASE; VASOCONSTRICTION; WATER RETENTION; ANIMAL; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANIMALIA;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 65749094793     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2009/752406     Document Type: Article

References (144)

1. Hansson G. K., Inflammation, atherosclerosis, and coronary artery disease The New England Journal of Medicine 2005 352 16 1685 1695
2. Libby P., Inflammatory mechanisms: the molecular basis of inflammation and disease Nutrition Reviews 2007 65 supplement 3 S140 S146
3. Toni R., Malaguti A., Castorina S., Roti E., Lechan R. M., New paradigms in neuroendocrinology: relationships between obesity, systemic inflammation and the neuroendocrine system Journal of Endocrinological Investigation 2004 27 2 182 186 (Pubitemid 38514813)
4. Jacoby D. S., Rader D. J., Renin-angiotensin system and atherothrombotic disease: from genes to treatment Archives of Internal Medicine 2003 163 10 1155 1164 (Pubitemid 36613067)
5. Schieffer B., Drexler H., Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases The American Journal of Cardiology 2003 91 12, supplement 1 12 18 (Pubitemid 36724890)
6. Tigerstedt R., Bergman P. G., Nere und Kreislauf Skandinavisches Archiv für Physiologie 1898 8 223 271
7. Fyhrquist F., Saijonmaa O., Renin-angiotensin system revisited Journal of Internal Medicine 2008 264 3 224 236
8. Guo C., Ju H., Leung D., Massaeli H., Shi M., Rabinovitch M., A novel vascular smooth muscle chymase is upregulated in hypertensive rats The Journal of Clinical Investigation 2001 107 6 703 715 (Pubitemid 32225356)
9. Nguyen G., Delarue F., Burcklè C., Bouzhir L., Giller T., Sraer J.-D., Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin The Journal of Clinical Investigation 2002 109 11 1417 1427 (Pubitemid 34596167)
10. Donoghue M., Hsieh F., Baronas E., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circulation Research 2000 87 5 E1 E9
11. Tipnis S. R., Hooper N. M., Hyde R., Karran E., Christie G., Turner A. J., A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase The Journal of Biological Chemistry 2000 275 43 33238 33243
12. Stevanovic R. D., Price D. A., Lansang M. C., Fisher N. D. L., Laffel L. M. B., Hollenberg N. K., Renin release in response to renin system blockade: activation of the renin system in type 1 diabetes mellitus Journal of the Renin-Angiotensin-Aldosterone System 2005 6 2 78 83 (Pubitemid 41699977)
13. Ferrario C. M., Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation Hypertension 2006 47 3 515 521 (Pubitemid 43843868)
14. Burrell L. M., Risvanis J., Kubota E., Myocardial infarction increases ACE2 expression in rat and humans European Heart Journal 2005 26 4 369 375 (Pubitemid 40283096)
15. Santos R. A., Ferreira A. J., Angiotensin-(1-7) and the renin-angiotensin system Current Opinion in Nephrology and Hypertension 2007 16 2 122 128 (Pubitemid 46254932)
16. Hirono Y., Yoshimoto T., Suzuki N., Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system Endocrinology 2007 148 4 1688 1696 (Pubitemid 46457130)
17. Tamura K., Tanaka Y., Tsurumi Y., The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function Current Hypertension Reports 2007 9 2 121 127 (Pubitemid 46779376)
18. Gendron L., Payet M. D., Gallo-Payet N., The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms Journal of Molecular Endocrinology 2003 31 3 359 372 (Pubitemid 38054511)
19. Cassis L. A., Police S. B., Yiannikouris F., Thatcher S. E., Local adipose tissue renin-angiotensin system Current Hypertension Reports 2008 10 2 93 98
20. Singh V. P., Le B., Khode R., Baker K. M., Kumar R., Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis Diabetes 2008 57 12 3297 3306
21. Singh V. P., Baker K. M., Kumar R., Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production American Journal of Physiology 2008 294 4 H1675 H1684
22. Kumar R., Singh V. P., Baker K. M., The intracellular renin-angiotensin system: implications in cardiovascular remodeling Current Opinion in Nephrology and Hypertension 2008 17 2 168 173
23. Schmieder R. E., Hilgers K. F., Schlaich M. P., Schmidt B. M., Renin-angiotensin system and cardiovascular risk The Lancet 2007 369 9568 1208 1219 (Pubitemid 46527856)
24. Graninger M., Reiter R., Drucker C., Minar E., Jilma B., Angiotensin receptor blockade decreases markers of vascular inflammation Journal of Cardiovascular Pharmacology 2004 44 3 335 339 (Pubitemid 39129452)
25. Shagdarsuren E., Wellner M., Braesen J.-H., Complement activation in angiotensin II-induced organ damage Circulation Research 2005 97 7 716 724 (Pubitemid 41416341)
26. Epstein M., Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift Journal of Hypertension 2001 19 5 829 842 (Pubitemid 32436945)
27. Sean Eardley K., Cockwell P., Macrophages and progressive tubulointerstitial disease Kidney International 2005 68 2 437 455 (Pubitemid 43323099)
28. Fukuhara M., Geary R. L., Diz D. I., Angiotensin-converting enzyme expression in human carotid artery atherosclerosis Hypertension 2000 35 1, part 2 353 359 (Pubitemid 30054199)
29. Ohishi M., Ueda M., Rakugi H., Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans Journal of Hypertension 1997 15 11 1295 1302 (Pubitemid 27453182)
30. Das U. N., Is angiotensin-II an endogenous pro-inflammatory molecule? Medical Science Monitor 2005 11 5 RA155 RA162 (Pubitemid 40790953)
31. Ferrario C. M., Strawn W. B., Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease The American Journal of Cardiology 2006 98 1 121 128 (Pubitemid 43902687)
32. Wang C.-H., Li S.-H., Weisel R. D., C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle Circulation 2003 107 13 1783 1790 (Pubitemid 36418360)
33. Schmidt-Ott K. M., Kagiyama S., Phillips M. I., The multiple actions of angiotensin II in atherosclerosis Regulatory Peptides 2000 93 1-3 65 77
34. Keidar S., Kaplan M., Hoffman A., Aviram M., Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins Atherosclerosis 1995 115 2 201 215
35. Morawietz H., Rueckschloss U., Niemann B., Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein Circulation 1999 100 9 899 902 (Pubitemid 29407168)
36. Schölkens B. A., Landgraf W., ACE inhibition and atherogenesis Canadian Journal of Physiology and Pharmacology 2002 80 4 354 359 (Pubitemid 34451253)
37. Linz W., Wohlfart P., Schölkens B. A., Becker R. H. A., Malinski T., Wiemer G., Late treatment with ramipril increases survival in old spontaneously hypertensive rats Hypertension 1999 34 2 291 295 (Pubitemid 29409230)
38. Wiemer G., Schölkens B. A., Becker R. H. A., Busse R., Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin Hypertension 1991 18 4 558 563
39. Wiemer G., Schölkens B. A., Linz W., Endothelial protection by converting enzyme inhibitors Cardiovascular Research 1994 28 2 166 172 (Pubitemid 24092764)
40. Malinski T., Meśros S., Patton S. R., Meśrosov́ A., Direct measurement of nitric oxide in the cardiovascular system Physiological Research 1996 45 4 279 284 (Pubitemid 26315561)
41. Kranzhöfer R., Browatzki M., Schmidt J., Kübler W., Angiotensin II activates the proinflammatory transcription factor nuclear factor- k B in human monocytes Biochemical and Biophysical Research Communications 1999 257 3 826 828 (Pubitemid 29301525)
42. Kranzhöfer R., Schmidt J., Pfeiffer C. A. H., Hagl S., Libby P., Kübler W., Angiotensin induces inflammatory activation of human vascular smooth muscle cells Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 7 1623 1629 (Pubitemid 29323820)
43. Brand K., Page S., Rogler G., Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion The Journal of Clinical Investigation 1996 97 7 1715 1722 (Pubitemid 26105480)
44. Guzik T. J., Harrison D. G., Endothelial NF- k B as a mediator of kidney damage: the missing link between systemic vascular and renal disease? Circulation Research 2007 101 3 227 229 (Pubitemid 47344070)
45. Henke N., Schmidt-Ullrich R., Dechend R., Vascular endothelial cell-specific NF- k B suppression attenuates hypertension-induced renal damage Circulation Research 2007 101 3 268 276 (Pubitemid 47344076)
46. Takahashi M., Suzuki E., Takeda R., Angiotensin II and tumor necrosis factor- β synergistically promote monocyte chemoattractant protein-1 expression: roles of NF- k B, p38, and reactive oxygen species American Journal of Physiology 2008 294 6 H2879 H2888
47. Blessing E., Preusch M., Kranzhöfer R., Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice Atherosclerosis 2008 199 2 295 303
48. Chinetti G., Griglio S., Antonucci M., Activation of proliferator- activated receptors β and γ induces apoptosis of human monocyte-derived macrophages The Journal of Biological Chemistry 1998 273 40 25573 25580 (Pubitemid 28475776)
49. Kato H., Ishida J., Nagano K., Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells Laboratory Investigation 2008 88 7 731 739
50. Pratt R. E., Angiotensin II and the control of cardiovascular structure Journal of the American Society of Nephrology 1999 10 supplement 11 S120 S128 (Pubitemid 29038176)
51. Sadoshima J., Cytokine actions of angiotensin II Circulation Research 2000 86 12 1187 1189 (Pubitemid 30436655)
52. Ruiz-Ortega M., Lorenzo O., Rupèrez M., Esteban V., Mezzano S., Egido J., Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator Contributions to Nephrology 2001 135 123 137 (Pubitemid 33352375)
53. Dzau V. J., Mechanism of protective effects of ACE inhibition on coronary artery disease European Heart Journal 1998 19 supplement J J2 J6 (Pubitemid 28427114)
54. Mancini G. B. J., Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease The American Journal of Medicine 1998 105 1, supplement 1 40S 47S (Pubitemid 28364425)
55. Adams K. F. Jr., Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease Coronary Artery Disease 1998 9 10 675 684 (Pubitemid 28566033)
56. Ding Y. A., MacIntyre D. E., Kenyon C. J., Semple P. F., Potentiation of adrenaline-induced platelet aggregation by angiotensin II Thrombosis and Haemostasis 1985 54 3 717 720 (Pubitemid 16195326)
57. Soejima H., Ogawa H., Yasue H., Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction Journal of the American College of Cardiology 1999 34 4 983 988 (Pubitemid 29500527)
58. Ichihara A., Hayashi M., Hirota N., Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells Hypertension Research 2003 26 11 915 921 (Pubitemid 37508970)
59. Apostolakis S., Krambovitis E., Vlata Z., Kochiadakis G. E., Baritaki S., Spandidos D. A., CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators Thrombosis Research 2007 121 3 387 395
60. Inukai T., Yoshida N., Wakabayashi S., Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus American Journal of the Medical Sciences 2005 329 5 222 227 (Pubitemid 40695448)
61. Schupp M., Janke J., Clasen R., Unger T., Kintscher U., Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- γ activity Circulation 2004 109 17 2054 2057 (Pubitemid 38620211)
62. Janke J., Schupp M., Engeli S., Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor- γ activation Journal of Hypertension 2006 24 9 1809 1816 (Pubitemid 44253243)
63. Jia N., Okamoto H., Shimizu T., A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin β1 expression Hypertension Research 2003 26 9 737 742 (Pubitemid 37258662)
64. Schölkens B. A., Becker R. H. A., Kaiser J., Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) Arzneimittel-Forschung 1984 34 10B 1417 1425 (Pubitemid 15201370)
65. Martorana P. A., Ruetten H., Goebel B., Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog Basic Research in Cardiology 1999 94 4 238 245 (Pubitemid 29419491)
66. Becker R. H. A., Wiemer G., Linz W., Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet Journal of Cardiovascular Pharmacology 1991 18 supplement 2 S110 S115
67. Chobanian A. V., Haudenschild C. C., Nickerson C., Hope S., Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit Hypertension 1992 20 4 473 477
68. Herńndez-Presa M., Bustos C., Ortego M., Angiotensin-converting enzyme inhibition prevents arterial nuclear factor- k B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis Circulation 1997 95 6 1532 1541 (Pubitemid 27142812)
69. Keidar S., Attias J., Coleman R., Wirth K., Schölkens B., Hayek T., Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin Journal of Cardiovascular Pharmacology 2000 35 1 64 72 (Pubitemid 30032895)
70. Akishita M., Horiuchi M., Yamada H., Inflammation influences vascular remodeling through AT2 receptor expression and signaling Physiological Genomics 2000 2 1 13 20
71. Akishita M., Shirakami G., Iwai M., Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice Journal of Hypertension 2001 19 6 1083 1088 (Pubitemid 32493642)
72. Candido R., Jandeleit-Dahm K. A., Cao Z., Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice Circulation 2002 106 2 246 253 (Pubitemid 34761307)
73. Hayek T., Kaplan M., Raz A., Keidar S., Coleman R., Aviram M., Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis Atherosclerosis 2002 161 1 65 74 (Pubitemid 34214822)
74. Miyazaki M., Sakonjo H., Takai S., Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet British Journal of Pharmacology 1999 128 3 523 529 (Pubitemid 29504739)
75. Chobanian A. V., The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis Clinical Cardiology 1990 13 6, supplement 7 43 48 (Pubitemid 20181208)
76. Linz W., Jessen T., Becker R. H. A., Schölkens B. A., Wiemer G., Long-term ACE inhibition doubles lifespan of hypertensive rats Circulation 1997 96 9 3164 3172 (Pubitemid 27500122)
77. Linz W., Wohlfart P., Schölkens B. A., Malinski T., Wiemer G., Interactions among ACE, kinins and NO Cardiovascular Research 1999 43 3 549 561 (Pubitemid 29369254)
78. Chobanian A. V., Haudenschild C. C., Nickerson C., Hope S., Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit Hypertension 1992 20 4 473 477
79. Kim S., Iwao H., Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases Pharmacological Reviews 2000 52 1 11 34 (Pubitemid 30127593)
80. Hope S., Brecher P., Chobanian A. V., Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis American Journal of Hypertension 1999 12 1 28 34 (Pubitemid 29118226)
81. Li J., Hirose N., Kawamura M., Arai Y., Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits Atherosclerosis 1999 143 2 315 326 (Pubitemid 29166912)
82. Strawn W. B., Chappell M. C., Dean R. H., Kivlighn S., Ferrario C. M., Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia Circulation 2000 101 13 1586 1593 (Pubitemid 30180896)
83. Koike H., New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist The American Journal of Cardiology 2001 87 8, supplement 1 33 36 (Pubitemid 32385760)
84. Schuhmacher A. J., Guerra C., Sauzeau V., Canamero M., Bustelo X. R., Barbacid M., A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition The Journal of Clinical Investigation 2008 118 6 2169 2179
85. van Kats J. P., Methot D., Paradis P., Silversides D. W., Reudelhuber T. L., Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice: direct and indirect effects of angiotensin II on the heart The Journal of Biological Chemistry 2001 276 47 44012 44017 (Pubitemid 37383971)
86. Daugherty K. K., Aliskiren American Journal of Health-System Pharmacy 2008 65 14 1323 1332
87. Nussberger J., Aubert J.-F., Bouzourene K., Pellegrin M., Hayoz D., Mazzolai L., Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine Hypertension 2008 51 5 1306 1311
88. Müller D. N., Derer W., Dechend R., Aliskiren-mode of action and preclinical data Journal of Molecular Medicine 2008 86 6 659 662
89. Imanishi T., Tsujioka H., Ikejima H., Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes Hypertension 2008 52 3 563 572
90. Fischer R., Dechend R., Qadri F., Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension Hypertension 2008 51 2 540 546
91. Pilz B., Shagdarsuren E., Wellner M., Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats Hypertension 2005 46 3 569 576 (Pubitemid 41376839)
92. Lu H., Rateri D. L., Feldman D. L., Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice The Journal of Clinical Investigation 2008 118 3 984 993
93. Sheth T., Parker T., Block A., Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure The American Journal of Cardiology 2002 90 5 496 500 (Pubitemid 35246039)
94. Jilma B., Li-Saw-Hee F. L., Wagner O. F., Beevers D. G., Lip G. Y. H., Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1 Clinical Science 2002 103 2 131 136
95. Koh K. K., Ahn J. Y., Han S. H., Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients Journal of the American College of Cardiology 2003 42 5 905 910 (Pubitemid 37059752)
96. Di Napoli M., Papa F., Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke Stroke 2003 34 12 2922 2929 (Pubitemid 37517770)
97. Tsikouris J. P., Suarez J. A., Simoni J. S., Ziska M., Meyerrose G. E., Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction Coronary Artery Disease 2004 15 4 211 217 (Pubitemid 38879572)
98. Schieffer B., Bünte C., Witte J., Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease Journal of the American College of Cardiology 2004 44 2 362 368 (Pubitemid 38960662)
99. Fliser D., Buchholz K., Haller H., Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation Circulation 2004 110 9 1103 1107 (Pubitemid 39319009)
100. Trevelyan J., Brull D. J., Needham E. W. A., Montgomery H. E., Morris A., Mattu R. K., Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene The American Journal of Cardiology 2004 94 5 564 569 (Pubitemid 39165833)
101. Tikiz C., Utuk O., Pirildar T., Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis Journal of Rheumatology 2005 32 11 2095 2101 (Pubitemid 41587851)
102. Krysiak R., Okopień B., Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease Pharmacological Reports 2008 60 4 514 523
103. Dzau V., Braunwald E., Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement American Heart Journal 1991 121 4, part 1 1244 1263
104. Mancini G. B. J., Henry G. C., Macaya C., Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study Circulation 1996 94 3 258 265 (Pubitemid 26266107)
105. Klingbeil A. U., John S., Schneider M. P., Jacobi J., Weidinger G., Schmieder R. E., AT 1 -receptor blockade improves augmentation index: a double-blind, randomized, controlled study Journal of Hypertension 2002 20 12 2423 2428 (Pubitemid 36026855)
106. Hornig B., Landmesser U., Kohler C., Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase Circulation 2001 103 6 799 805 (Pubitemid 32163876)
107. Schmieder R. E., Delles C., Mimran A., Fauvel J. P., Ruilope L. M., Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes Diabetes Care 2007 30 6 1351 1356 (Pubitemid 46871137)
108. Schiffrin E. L., Park J. B., Intengan H. D., Touyz R. M., Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan Circulation 2000 101 14 1653 1659 (Pubitemid 30196624)
109. Bader M., Ganten D., Update on tissue renin-angiotensin systems Journal of Molecular Medicine 2008 86 6 615 621
110. Anderson T. J., Elstein E., Haber H., Charbonneau F., Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) Journal of the American College of Cardiology 2000 35 1 60 66 (Pubitemid 30061260)
111. Perticone F., Ceravolo R., Pujia A., Prognostic significance of endothelial dysfunction in hypertensive patients Circulation 2001 104 2 191 196 (Pubitemid 32655837)
112. Sierra C., de la Sierra A., Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers Current Opinion in Nephrology and Hypertension 2005 14 5 435 441 (Pubitemid 41152705)
113. Lonn E. M., Yusuf S., Dzavik V., Effects of Ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) Circulation 2001 103 7 919 925 (Pubitemid 32183795)
114. MacMahon S., Sharpe N., Gamble G., Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease Journal of the American College of Cardiology 2000 36 2 438 443 (Pubitemid 30624005)
115. Teo K. K., Burton J. R., Buller C. E., Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 2000 102 15 1748 1754
116. Cashin-Hemphill L., Holmvang G., Chan R. C., Pitt B., Dinsmore R. E., Lees R. S., Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet The American Journal of Cardiology 1999 83 1 43 47 (Pubitemid 29036645)
117. Nissen S. E., Tuzcu E. M., Libby P., Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial The Journal of the American Medical Association 2004 292 18 2217 2225 (Pubitemid 39473159)
118. Olsen M. H., Wachtell K., Neland K., Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy Blood Pressure 2005 14 3 177 183 (Pubitemid 41015717)
119. Weir M. R., Effects of renin-angiotensin system inhibition end-organ protection: can we do better? Clinical Therapeutics 2007 29 9 1803 1824 (Pubitemid 350214460)
120. Ferrario C. M., Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research Journal of the Renin-Angiotensin-Aldosterone System 2006 7 1 3 14 (Pubitemid 43891239)
121. Prisant L. M., Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents The American Journal of Medicine 2008 121 8, supplement 1 S8 S15
122. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The New England Journal of Medicine 2000 342 3 145 153 (Pubitemid 30051645)
123. Sever P. S., Poulter N. R., Elliott W. J., Blood pressure reduction is not the only determinant of outcome Circulation 2006 113 23 2754 2774 (Pubitemid 43947993)
124. Fox K. M., Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) The Lancet 2003 362 9386 782 788 (Pubitemid 37093919)
125. Braunwald E., Domanski M. J., Fowler S. E., Angiotensin-converting-enzyme inhibition in stable coronary artery disease The New England Journal of Medicine 2004 351 20 2058 2068 (Pubitemid 39482499)
126. Friedrich E. B., Teo K. K., Böhm M., ACE inhibition in secondary prevention: are the results controversial? Clinical Research in Cardiology 2006 95 2 61 67 (Pubitemid 43263068)
127. Dagenais G. R., Pogue J., Fox K., Simoons M. L., Yusuf S., Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials The Lancet 2006 368 9535 581 588 (Pubitemid 44209181)
128. Yusuf S., Teo K., Anderson C., Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial The Lancet 2008 372 9644 1174 1183
129. Ripley T. L., Harrison D., The power to TRANSCEND The Lancet 2008 372 9644 1128 1130
130. Dahlöf B., Devereux R. B., Kjeldsen S. E., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol The Lancet 2002 359 9311 995 1003 (Pubitemid 34286536)
131. Watanabe T., Barker T. A., Berk B. C., Angiotensin II and the endothelium: diverse signals and effects Hypertension 2005 45 2 163 169 (Pubitemid 40179951)
132. Moser M., Rosendorff C., White W. B., Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension? Journal of Clinical Hypertension 2008 10 6 489 496
133. Schulman I. H., Raij L., The angiotensin II type 2 receptor: what is its clinical significance? Current Hypertension Reports 2008 10 3 188 193
134. Messerli F. H., Williams B., Ritz E., Essential hypertension The Lancet 2007 370 9587 591 603 (Pubitemid 47247855)
135. Matchar D. B., McCrory D. C., Orlando L. A., Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension Annals of Internal Medicine 2008 148 1 16 29
136. Yusuf S., Teo K. K., Pogue J., Telmisartan, ramipril, or both in patients at high risk for vascular events The New England Journal of Medicine 2008 358 15 1547 1559
137. Mann J. F., Schmieder R. E., McQueen M., Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial The Lancet 2008 372 9638 547 553
138. Phillips C. O., Kashani A., Ko D. K., Francis G., Krumholz H. M., Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials Archives of Internal Medicine 2007 167 18 1930 1936 (Pubitemid 47606631)
139. Kunz R., Friedrich C., Wolbers M., Mann J. F. E., Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease Annals of Internal Medicine 2008 148 1 30 48
140. McMurray J. J. V., Östergren J., Swedberg K., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial The Lancet 2003 362 9386 767 771 (Pubitemid 37093916)
141. Ferrari P., Marti H.-P., Pfister M., Frey F. J., Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade Journal of Hypertension 2002 20 1 125 130
142. Skeggs L. T. Jr., Kahn J. R., Lentz K., Shumway N. P., The preparation,
143. Parving H.-H., Persson F., Lewis J. B., Lewis E. J., Hollenberg N. K., Aliskiren combined with losartan in type 2 diabetes and nephropathy The New England Journal of Medicine 2008 358 23 2433 2446
144. Westermann D., Schmieder R., Schultheiss H.-P., Tschöpe C., Renin inhibitors, clinical experience Journal of Molecular Medicine 2008 86 6 691 695